News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

KineMed, Inc. Announces Agreement With EMD Serono To Identify Protein And Lipid Biomarkers For Multiple Sclerosis


1/13/2014 7:44:58 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed, Inc. (www.kinemed.com) today announced an agreement with EMD Serono to apply KineMed’s mass spectrometric Dynamic Proteomics and lipids platforms to the discovery of protein and lipid biomarkers for multiple sclerosis.

Myelin breakdown and synthesis is a fundamental process underlying progression and resolution of demyelinating disorders such as multiple sclerosis (MS). Sensitive biomarkers of myelin synthesis are necessary for monitoring the in vivo response to candidate remyelinating agents. KineMed’s proprietary technology platform will be used to discover biomarkers that will allow EMD Serono to track and monitor rates of myelin breakdown and repair in the living brain.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES